Why Syndax (SNDX) Is Slipping: 25% Decline Amid Weak Pipeline & Market Pressure
Explore why Syndax (SNDX) shares are slipping below 200‑day SMA, amid weak liquidity and a stagnant oncology pipeline—what it means for investors.
- SYNDAX PHARMACEUTICALS INC
- United States
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
3 minutes to read
